Alpha Cognition (ACOG) Other Non-Current Assets (2024 - 2025)
Alpha Cognition (ACOG) posted quarterly Other Non-Current Assets of $95032.0 for Q1 2025, down 88.85% year-over-year from $852296.0 in Q1 2024, and up 107.88% quarter-over-quarter from $45714.0 in Q4 2024.
Alpha Cognition (ACOG) Other Non-Current Assets (2024 - 2025) Analysis & Trends
Alpha Cognition's Other Non-Current Assets history runs 2 years deep, the most recent figure standing at $95032.0 for Q1 2025.
- In Q1 2025, Other Non-Current Assets fell 88.85% year-over-year to $95032.0; the TTM figure through Mar 2025 stood at $95032.0 (down 88.85% YoY), while the FY2024 annual figure was $45714.0, changed N/A from the prior year.
- Other Non-Current Assets for Q1 2025 stood at $95032.0, up from $45714.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $852296.0 in Q1 2024, with the low at $45714.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Alpha Cognition | 219.48 Mn | 178.04 Mn | 5.70 Mn | 223,096.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 95,032.00 |
| Dec 31, 2024 | 45,714.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 114,286.00 |
| Mar 31, 2024 | 852,296.00 |